Clinical Trials

Inclusion Criteria

• Patient must provide written informed consent prior to participating in this protocol.
• Patient must have been prescribed TECELRA.
• Patient’s commercially manufactured product does not meet the commercial release specification.
• Repeat manufacture is not feasible or is not clinically appropriate per Investigator assessment in consultation with Adaptimmune.
• Repeat leukapheresis is not feasible or is not clinically appropriate per Investigator assessment.
• The Investigator has confirmed a favorable benefit:risk profile, following sponsor evaluation of the NC afami-cel, and deems proceeding with treatment under this EAP is in the best interest of the patient.
• Patient deemed medically fit and stable to receive NC afami-cel per Investigator assessment.
• Female patients with reproductive potential must have a negative serum or urine pregnancy test within 7 days of initiating lymphodepleting chemotherapy.

Exclusion Criteria

• Patient has contraindication(s) as per the TECELRA USPI.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 8/09/2024. Questions regarding updates should be directed to the study team contact.